Genomic Health has entered an agreement to exclusively license Almac Group’s technology and intellectual property to further develop, validate and commercialize a multi-gene test to predict benefit from DNA damage-based chemotherapy drugs, such as anthracycline-based regimens, in breast cancer. This test would be particularly useful for high-risk breast cancer patients who are eligible for chemotherapy based on their Oncotype DX score. Genomic Health will identify a study cohort for the validat...